BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial

Melinda Zeron Mullins, Konia M Trouton, Melinda Zeron Mullins, Konia M Trouton

Abstract

Background: Bacterial vaginosis is associated with increased transmission of sexually transmitted infections, preterm labor, post-surgical infections, and endometritis. Current treatment for symptomatic bacterial vaginosis includes antibiotics, such as metronidazole, which are 70-80 % effective at one month after treatment and result in high recurrence rates and secondary candida infections. Intravaginal boric acid has been used for over a hundred years to treat vaginal infections, such as bacterial vaginosis. Boric acid is inexpensive, accessible, and has shown to be an effective treatment for other infections, such as vaginal candidiasis. To date, there has been no clinical trial evaluation of boric acid effectiveness to treat bacterial vaginosis.

Methods/design: The BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) trial is a randomized, double-blinded, multicenter study. The study will enroll a minimum of 240 women of 16-50 years of age who are symptomatic with bacterial vaginosis. Eligible participants will have Amsel and Nugent scores confirming bacterial vaginosis. Women who are pregnant or menopausal or have other active co-infections will be excluded. Consenting participants who meet exclusion and inclusion criteria will be randomly assigned to one of three treatment groups: boric acid, metronidazole, or an inert placebo. Self-administration of treatment intravaginally for 10 days will be followed by clinical assessment at 7 and 30 days (days 17 and 40, respectively) after the end of the treatment phase. Primary outcome is a non-inferiority, per-protocol comparison of the effectiveness of boric acid with that of metronidazole at day 17, as measured by the Nugent score in 16-50 year olds. Secondary outcomes include: non-inferiority, intention-to-treat comparison of effectiveness of boric acid with that of metronidazole at day 17, analysis for both per-protocol and intention-to-treat at day 40, and safety considerations, including adverse effects requiring patient discontinuation of treatment.

Discussion: This study will be the first to determine whether intravaginal boric acid is non-inferior to metronidazole in the treatment of bacterial vaginosis in symptomatic women.

Trial registration: ClinicalTrials.gov NCT00799214, registered online Nov 10, 2008.

References

    1. Nyirjesy P, McIntosh MJ, Steinmetz JI, Schumacher RJ, Joffrion JL. The effects of intravaginal clindamycin and metronidazole therapy on vaginal Mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis. 2007;34(4):197–202. doi: 10.1097/01.olq.0000235152.98601.d7.
    1. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis. 2003;37:319–25. doi: 10.1086/375819.
    1. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis. 2003;36:663–8. doi: 10.1086/367658.
    1. Yudin MH, Money DM, Infectious Diseases Committee Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can. 2008;30(8):702–16.
    1. Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9 doi: 10.1371/journal.pmed.1001251.
    1. Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodi N, Kasaro MP, Ramjee G, Hoffman IF, Abdool Karim SS. Bacterial vaginosis and the risk of Trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis. 2014;41:123–8. doi: 10.1097/OLQ.0000000000000075.
    1. Gibbs RS. Asymptomatic bacterial vaginosis: is it time to treat? Am J Obs Gyne. 2007;196:495–6. doi: 10.1016/j.ajog.2007.04.001.
    1. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291:1368–79. doi: 10.1001/jama.291.11.1368.
    1. Canadian STI Guidelines: Section 4. Management and treatment of specific syndromes: vaginal discharge (bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis) 2013. . Accessed 20 May 2015.
    1. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301.
    1. Wain AM. Metronidazole vaginal cream 0.75% (MetroGel-Vaginal): a brief review. Inf Dis Obs Gyne. 1998;6:3–7. doi: 10.1155/S1064744998000027.
    1. Simoes JA, Bahamondes LG, Camargo RP, Alves VM, Zaneveld LJ, Waller DP, Schwartz J, Callahan MM, Mauck CK. A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. Br J Clin Pharm. 2006;61:211–7. doi: 10.1111/j.1365-2125.2005.02550.x.
    1. Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother. 2014;15(5):645–57. doi: 10.1517/14656566.2014.881800.
    1. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract. 1995;41:443–9.
    1. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Inf Dis. 1999;28:S57–65. doi: 10.1086/514725.
    1. Hay P. Bacterial vaginosis. Medicine. 2005;33:58–61. doi: 10.1383/medc.2005.33.10.58.
    1. Schmid GP. The epidemiology of bacterial vaginosis. Int J Gyne Obs. 1999;67:S17–20. doi: 10.1016/S0020-7292(99)00133-2.
    1. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. JID. 2006;193:1478–87. doi: 10.1086/503780.
    1. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, Soper D, Ohmit SE, Hillier SL. Suppressive antibacterial therapy with 0.75 % metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obs Gyne. 2006;194:1283–9. doi: 10.1016/j.ajog.2005.11.041.
    1. Hanson JM, McGregor JA, Hillier SL, Eschenbach DA, Kreutner AK, Galask RP, Martens M. Metronidazole for bacterial vaginosis: a comparison of vaginal gel vs. oral therapy. J Reprod Med. 2000;45:889–96.
    1. Sobel JD. Bacterial vaginosis. In: Post TW, editor. UpToDate®. Waltham, MA: Wolters Kluwer; 2015.
    1. Keller Van Slyke K, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obs Gyne. 1981;141:145–8.
    1. Swate TE, Weed JC. Boric acid treatment of vulvovaginal candidiasis. Obs Gyne. 1974;43:893–5.
    1. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs boric acid for treating chronic mycotic vulvovaginitis. J Reprod Med. 1991;36:593–7.
    1. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Inf Dis. 1997;24:649–52. doi: 10.1093/clind/24.4.649.
    1. Guaschino S, De Seta F, Sartore A, Ricci G, De Santo D, Piccoli M, Alberico S. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obs Gyne. 2001;184:598–602. doi: 10.1067/mob.2001.111938.
    1. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obs Gyne. 2003;189:1297–300. doi: 10.1067/S0002-9378(03)00726-9.
    1. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V, Kochupillai N. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care. 2007;30(2):312–7. doi: 10.2337/dc06-1469.
    1. Ray D, Goswami R, Dadhwal V, Goswami D, Banerjee U, Kochupillai N. Prolonged (3 month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis. J Infect. 2007;55(4):374–7. doi: 10.1016/j.jinf.2007.06.008.
    1. Spence D. Candidiasis (vulvovaginal) BMJ Clin Evid. 2010;2010:0815.
    1. Donders GG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gyne Obs Invest. 2010;70(4):306–21. doi: 10.1159/000314022.
    1. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732–4. doi: 10.1097/OLQ.0b013e3181b08456.
    1. Krohn MA, Hillier SL, Eschenbach DA. Comparison of methods for diagnosing bacterial vaginosis among pregnant women. J Clin Microbiol. 1989;27(6):1266–71.
    1. sealed envelope™. Power (sample size) calculators. . Accessed 3 June 2015.
    1. Hida E, Tango T. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints. J Biopharm Stat. 2013;23(4):774–89. doi: 10.1080/10543406.2013.789893.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi